NCT02186626View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
West Nile Virus
Interventions
BIOLOGICAL

WN/DEN4Δ30 Vaccine

WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.

BIOLOGICAL

Placebo

Delivered by subcutaneous injection in the deltoid region of the upper arm.

Trial Locations (2)

21205

Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore

05401

Vaccine Testing Center, University of Vermont College of Medicine (UVM), Burlington

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02186626 - Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age | Biotech Hunter | Biotech Hunter